Legal regimes surrounding naloxone access: Considerations for prescribers

American Journal of Drug and Alcohol Abuse

Volumn 42, Issue 2, 2016, Pages 117-128

  Brodrick, Joy E ^a   Brodrick, Collin K ^b   Adinoff, Bryon ^a,c  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^b Medical Malpractice   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Drug overdose; Legal liability; Naloxone; Opioids; Public health

Indexed keywords

ANTIDOTE; NALOXONE; NARCOTIC ANTAGONIST;

DRUG INTOXICATION; DRUG LEGISLATION; DRUG OVERDOSE; DRUG SAFETY; DRUG UTILIZATION; HEALTH EDUCATION; HUMAN; LEGAL ASPECT; LEGAL LIABILITY; PHYSICIAN; PRESCRIPTION; REVIEW; HEALTH CARE DELIVERY; LEGISLATION AND JURISPRUDENCE; OPIOID-RELATED DISORDERS; UNITED STATES;

DRUG OVERDOSE; HEALTH SERVICES ACCESSIBILITY; HUMANS; LIABILITY, LEGAL; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; UNITED STATES;

EID: 84958049725     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.3109/00952990.2015.1109648     Document Type: Review

References (158)

1. Kim D, Irwin KS, Khoshnood K. Expanded access to naloxone: options for critical response to the epidemic of opioid overdose mortality. Am J Public Health 2009;99:402-407.
2. National Center for Injury Prevention and Control. Opioid Painkiller Prescribing. Centers for Disease Control and Prevention website. Available from: http://www.cdc.gov/vitalsigns/opioid-prescribing/[last accessed 28 Nov 2014].
3. National Institute on Drug Abuse. Overdose Death Rates. National Institute on Drug Abuse website. Available from: http://www.drugabuse.gov/relatedtopics/trends-statistics/overdose-death-rates [last accessed 19 March 2015].
4. Rudd RA, Paulozzi LJ, Bauer MJ, Burleson RW, Carlson RE, Dao D, Davis JW, et al. Increases in heroin overdose deaths-28 states, 2010 to 2012. MMWR 2014;63:849-854.
5. Behavioral Health Coordinating Committee, Prescription Drug Abuse Subcommittee, U.S. Department of Health and Human Services. Addressing Prescription Drug Abuse in the United States Current Activities and Future Opportunities. Centers for Disease Control and Prevention website. A v a i l a b l e f r o m : h t t p : //w w w . c d c . g o v /HomeandRecreationalSafety/pdf/HHS-Prescription-Drug-Abuse-Report-09.2013.pdf. [last accessed 8 June 2015].
6. Gray E. Heroin gains popularity as cheap doses flood the U.S. Time; 4 February, 2014. Available from: http://time.com/4505/heroin-gains-popularity-as-cheapdoses-flood-the-u-s/.
7. Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry 2014;71:821-826.
8. Burris S, Beletsky L, Castagna C, Casey C, Colin C, McLaughlin, JM. Stopping an invisible epidemic: legal issues in the provision of naloxone to prevent opioid overdose. Drexel Law Rev 2009;1:273-339.
9. Pattinson KT. Opioids and the control of respiration. Br J Anaesthesia 2008;100:747-758.
10. Lexi-Comp Online, Lexi-Drugs, Hudson, Ohio: Lexi-Comp, Inc.; 28 November 2014.
11. U.S. Food and Drug Administration. FDA approves new hand-held auto-injector to reverse opioid overdose. U.S. Food and Drug Administration website. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm391465.htm. April 3, 2014 [last accessed 28 Nov 2014].
12. EVZIO [package insert]. Richmond, VA: Kaleo Incorporated; 2014.
13. Robertson TM, Hendey GW, Stroh G, Shalit M. Intranasal naloxone is a viable alternative to intravenous naloxone for prehospital narcotic overdose. Prehosp Emergency Care 2009;13:512-515.
14. Merlin MA, Saybolt M, Kapitanyan R, et al. Intranasal naloxone delivery is an alternative to intravenous naloxone for opioid overdoses. Am J Emergency Med 2010;28:296-303.
15. Sabzghabaee AM, Eizadi-Mood N, Yaraghi A, Zandifar S. Naloxone therapy in opioid overdose patients: intranasal or intravenous? A randomized clinical trial. Arch Medical Sci 2014;10:309-314.
16. Davis CS, Ruiz S, Glynn P, Picariello G, Walley AY. Expanded access to naloxone among firefighters, police officers, and emergency medical technicians in Massachusetts. Am J Public Health 2014;104:e7-9.
17. Davis CS, Southwell JK, Niehaus VR, Walley AY, Dailey MW. Emergency medical services naloxone access: a national systematic legal review. Academic Emergency Med 2014;21:1173-1177.
18. Sporer KA, Kral AH. Prescription naloxone: a novel approach to heroin overdose prevention. Annals Emergency Med 2007;49:172-177.
19. Centers for Disease Control and Prevention. Opioid overdose prevention programs providing naloxone to laypersons-United States, 2014. MMWR 2015;64:631-635.
20. Clark AK, Wilder CM, Winstanley EL. A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med 2014;8:153-163.
21. DOPE Project/San Francisco Department of Public Health. Overdose Rescue & Naloxone: Long-format training. Harm Reduction Coalition website. Available from: http://harmreduction.org/issues/overdose-preven tion/tools-best-practices/training-materials/curriculafor-users/. [last accessed 24 May 2015].
22. Harm Reduction Coalition. Naloxone Program Case Studies. Harm Reduction Coalition website. Available from: http://harmreduction.org/issues/overdose-preven tion/tools-best-practices/naloxone-program-case-stu dies/[last accessed 24 May 2015].
23. Vermont Department of Health. Overdose Prevention & Naloxone Enrollment Form. Vermont Department of Health website. Available from: http://healthver mont.gov/adap/treatment/naloxone/documents/naloxone-od-enrollment-form.pdf. [last accessed 24 May 2015].
24. Boston Medical Center. Intranasal Naloxone Kit Discharge Order Protocol. Prescribe to Prevent website. Available from: http://prescribetoprevent.org/wp-con tent/uploads/NaloxoneKitDischargeOrderProtocol-091313.pdf. September 2013. [last accessed 24 May 2015].
25. Doe-Simkins M, Quinn E, Xuan Z, et al. Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: a retrospective cohort study. BMC Public Health 2014;14:297.
26. Walley AY, Xuan Z, Hackman HH, Quinn E, Doe-Simkins M, Sorensen-Alawad A, Ruiz S, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ 2013;346:f174.
27. Seal KH, Thawley R, Gee L, Bamberger J, Kral AH, Ciccarone D, Downing M, et al. Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. J Urban Health 2005;82:303-311.
28. Wagner KD, Valente TW, Casanova M, Partovi SM, Mendenhall BM, Hundley JH, Gonzalez M, et al. Evaluation of an overdose prevention and response training programme for injection drug users in the Skid Row area of Los Angeles, CA. Int J Drug Policy 2010;21:186-193.
29. U.S. Department of Justice Drug Enforcement Administration. Lists of: Scheduling Actions Controlled Substances Regulated Chemicals. Office of Diversion Control website. Available from: http://www. deadiversion.usdoj.gov/schedules/orangebook/orange book.pdf. [last accessed 18 Aug 2015].
30. Naloxone-sold to and administered by qualified first responders, V.A.M.S. 190.255 (2014).
31. Opioid antagonist; prescription and dispensing permitted by authorized licensed health care providers to persons at risk of opioid-related overdose or persons in position to assist person at risk; standing distribution orders; overdose prevention and treatment training; immunity from liability, Cal. Civil Code 1714.22 (2014).
32. National Alliance for Model State Drug Laws. Good Samaritan and Naloxone Bill Status Report-Carryover 2015 and Special Sessions. National Alliance for Model State Drug Laws website. Available from: http://www. namsdl.org/library/5ADFAF25-B7DA-7305-7CD278B0EC0599CE/. [last accessed 18 Aug 2015].
33. Opioid antagonist-prescriptions authorized; administration; liability, Ala.Code 1975 20-2-4 (1975).
34. Drugs and medicine-physicians and dentists-opioid antagonist-drug overdoses, H.B. 208, Alabama 2015 Regular Session (2015).
35. Administration of opiate antagonists; training; immunity; designation by director, A.R.S. 36-2228 (2015).
36. Opioid antagonist-Immunity, A.C.A. 20-13-1604 (2015).
37. Furnishing of naloxone hydrochloride; development of standardized procedures or protocols, Cal. Bus & Prof. Code 4052.01 (2015).
38. Protocol for Pharmacists Furnishing Naloxone Hydrochloride, 16 CCR 1746.3 (2015).
39. Unprofessional conduct, C.R.S.A. 12-36-117 (2015).
40. Grounds for discipline, C.R.S.A. 12-38-117 (2015).
41. Prescribing opiate antagonists-definitions, C.R.S.A. 12-38-125.5 (2015).
42. Rules, C.R.S.A. 12-42.5-105 (2015).
43. Prescription required-exception-dispensing opiate antagonists-definitions, C.R.S.A. 12-42.5-120 (2015).
44. Unprofessional conduct-grounds for discipline, C.R. S.A. 12-42.5-123 (2015).
45. Persons rendering emergency assistance through the administration of an opiate antagonist-limited immunity-legislative declaration-definitions, C.R.S.A. 13-21-108.7 (2015).
46. Immunity for a person who administers an opiate antagonist during an opiate-related drug overdose event-definitions, C.R.S.A. 18-1-712 (2015).
47. Immunity for prescribing, dispensing or administering an opioid antagonist to treat or prevent a drug overdose, C.G.S.A. 17a-714a (2015).
48. Community-based Naloxone access program, 16 DelC. 138 (2014).
49. Administration of naloxone by peace officers and the Community-Based Naloxone Access Program, 16 Del. C. 3001G (2014).
50. Seeking health care for an overdose victim, D.C. Code 7-403 (2013).
51. Emergency treatment for suspected opioid overdose, Fla. Stat. 381.887 (2015).
52. Opioid antagonists, Ga. Code 26-4-116.2 (2014).
53. Opioid antagonists; administration; issuance; liability, Ga. Code 31-11-55.1 (2014).
54. Practice of pharmacy, I.C. 54-1704 (2015).
55. Violations and penalties, I.C. 54-1732 (2015).
56. Opioid antagonists, I.C. 54-1733B (2015).
57. Possession of legend drugs, I.C. 54-1734 (2015).
58. Drug Overdose Prevention Program, 20 ILCS 301/5-23 (2010).
59. Prescriber defined, IC 16-42-27-1 (2015).
60. Prescribing or dispensing an overdose intervention drug without examination; conditions, IC 16-42-27-2 (2015).
61. Immunity from civil liability, IC 16-42-27-3 (2015).
62. Overdose intervention drug, IC 16-18-2-263.9 (2015).
63. Provider prescribing or dispensing naloxone; administration by third party; use of naloxone by person or agency authorized to administer medication; immunity from liability; administrative regulations; use of naloxone by schools, KRS 217.186 (2015).
64. Naloxone; first responder; prescription; administration to third party; limitation of liability, LA R.S. 40:978.1 (2014).
65. Naloxone; prescription; dispensing; administration by third party; limitation of liability, LA R.S. 40:978.2 (2015).
66. Naloxone hydrochloride, 22 M.R.S.A. 2353 (2014).
67. Overdose Response Program, MD Health Gen T. 13, Subt. 31 (2015).
68. Prescription; restrictions on issuance, M.G.L.A. 94C 19 (2012).
69. Opioid antagonist, M.G.L.A. 94C 19B (2014).
70. Immunity from prosecution under Secs. 34 or 35 for persons seeking medical assistance for self or other experiencing drug-related overdose, M.G.L.A. 94C 34A (2012).
71. Definitions, M.C.L.A. 28.541 (2015).
72. Definitions; terms commencing o and p, M.C.L.A. 333.1106 (2014).
73. Report on opioid-related fatalities, M.C.L.A. 333.7421 (2014).
74. Prescribing, dispensing, possessing, or administering opioid antagonist; powers and duties of prescriber, dispensing prescriber, and pharmacist; civil liability, M.C.L.A. 333.17744b (2014).
75. Opioid antagonist; administration to individual suffering opioid-related overdose, M.C.L.A. 691.1503 (2014).
76. Legend drugs, who may prescribe, possess, M.S.A 151.37 (2014).
77. Good samaritan overdose prevention, M.S.A. ST 604A.04 (2014).
78. The Emergency Response and Overdose Prevention Act, H.B. 692, Mississippi Regular Session (2015).
79. Naloxone, Neb.Rev.St. LB 390, 11 (2015).
80. Establishes an opioid overdose prevention policy for Nevada, S.B. 459, Nevada 78th Legislature (2015).
81. Persons and Corporations Exempted, N.H. Rev. Stat. 318-B:15 (2015).
82. Overdose Prevention, 24 NJ ST Subt. 1, Ch. 6J (2013).
83. Establishment of sterile syringe access program by municipalities, N.J.S.A. 26:5C-28 (2015).
84. Authority to administer opioid antagonists; release from liability, N.M.S.A. 1978, 24-23-1 (2015).
85. Health care professionals; release from liability, N.M.S. A. 1978, 24-23-2 (2015).
86. Authorization to administer opioid antagonists, N.M. Admin. Code 7.32.7 (2015).
87. Pharmacist, N.M. Admin. Code 16.19.4 (2015).
88. Pharmacist prescriptive authority, N.M. Admin. Code 16.19.26 (2015).
89. Opioid overdose prevention, NY Pub health 3309 (2015).
90. Opioid overdose prevention programs, 10 NYCRR 80.138 (2015).
91. Treatment of overdose with opioid antagonist; immunity, N.C.G.S.A. 90-106.2 (2015).
92. A Bill for an Act to create and enact a new section to chapter 23-01 and a new subsection to section 43-15-11 of the North Dakota Century Code, relating to immunity from liability related to opioid antagonists and limited prescriptive authority for Naloxone rescue kits, S.B. 2104, 64th Legislative Assembly of North Dakota (2015).
93. Immunity for administration of naloxone, R.C. 2925.61 (2015).
94. Furnishing supply of, or issuing prescription for, naloxone without examining individual to whom it may be administered; immunity, R.C. 4723.488 (2015).
95. Priority of sale, distribution, and delivery of naloxone; immunity, R.C. 4729.511 (2014).
96. Furnishing supply of, or issuing prescription for, naloxone without examining individual to whom it may be administered; immunity, R.C. 4730.431 (2015).
97. Furnishing supply of, or issuing prescription for, naloxone without examining individual to whom it may be administered; immunity, R.C. 4731.94 (2015).
98. Administration of opiate antagonists, 63 Okl.St.Ann. 1-2506.1 (2015).
99. Prescription of opiate antagonists to family members, 63 Okl.St.Ann. 1-2506.2 (2015).
100. Sale or disposition of Naloxone, 63 Okl.St.Ann. 2-312.2 (2015).
101. Establishment of protocols and training on lifesaving treatments for opiate overdose; provision of training and supplies; immunity, O.R.S. 689.681 (2015).
102. Programs to treat allergic response or hypoglycemia, Oregon Administrative Code, Chapter 333, Division 55 (2015).
103. Purpose, OAR 333-055-0100 (2015).
104. Definitions, OAR 333-055-0105 (2015).
105. Educational training, OAR 333-055-0110 (2015).
106. Certificate of completion of training, OAR 333-055-0115 (2015).
107. Definitions, OAR 855-041-2310 (2015).
108. Naloxone, OAR 855-041-2330 (2015).
109. Drug overdose response immunity, 35 P.S. 780-113.7 (2014).
110. Drug overdose medication, 35 P.S. 780-113.8 (2014).
111. Rules and Regulations pertaining to opioid overdose prevention and reporting, 31 RI Adc D. 2, R.9 (2015).
112. Overdose prevention and education, R.I. Admin. Code 46-1-13:46.0 (2015).
113. South Carolina Overdose Prevention Act, H.B. 3083, South Carolina General Assembly 121st Session (2015).
114. Opioid antagonist defined, SDCL 34-20A-99 (2015).
115. An act to provide for the possession and administration of opioid antagonists by first responders for the treatment of drug overdoses, S.B. 14, South Dakota Regular Session of the 90th Legislature (2015).
116. Opioid antagonists; usage; liability, T.C.A. 63-1-152 (2014).
117. An act relating to the prescription, administration, and possession of certain opioid antagonists for the treatment of suspected opioid overdoses, S.B. 1462, Texas 84th Legislature (2015).
118. Emergency Administration of Opiate Antagonist Act, Utah Code Annotated, Title 26, Chapter 55 (2015).
119. Opiate antagonist-immunity from liability, U.C.A. 58-17b-507 (2015).
120. Opiate antagonist-exclusion from unprofessional or unlawful conduct, U.C.A. 58-31b-703 (2015).
121. Naloxone hydrochloride; dispensing or furnishing, 26 V.S.A. 2080 (2015).
122. Prevention and treatment of opioid-related overdoses, 18 V.S.A. 4240 (2015)
123. Persons rendering emergency care, obstetrical services exempt from liability, VA Code Ann. 8.01-225 (2015).
124. Professional use by practitioners, VA Code Ann. 54.1-3408 (2015).
125. Medical assistance-drug-related overdose-naloxone-prosecution for possession, RCW 69.50.315 (2015).
126. Opioid overdose medication [Tentative classification and name line supplied by publisher], RCW 69.41.0001 (2015).
127. Prescription requirements-penalty, RCW 69.41.040 (2015).
128. Access to Opioid Antagonists Act, West Virginia Code, Chapter 16, Article 46 (2015).
129. Opioid antagonists, W.S.A. 256.40 (2014).
130. Disciplinary proceedings and actions, W.S.A. 441.07 (2014).
131. Prescriptions for and delivery of opioid antagonists, W. S.A. 441.18 (2014).
132. Prescriptions for and delivery of opioid antagonists, W. S.A. 448.037 (2014).
133. Definitions, W.S.A. 450.01 (2015).
134. Prescription drugs and prescription devices, W.S.A. 450.11 (2015).
135. Civil liability exemption; emergency medical care, W.S. A. 895.48 (2014).
136. Office of the Attorney General State of Maryland, Opinion No. 03-009, 2003 WL 21003267 (MdA.G.).
137. License required to practice medicine, MD Code, Health Occupations, 14-601 (2013).
138. Effect of violation, W.Y.1977 33-26-410 (2003).
139. Beletsky L, Ruthazer R, Macalino GE, Rich JD, Tan L, Burris S. Physicians' knowledge of and willingness to prescribe naloxone to reverse accidental opiate overdose: challenges and opportunities. J Urban Health 2007;84:126-136.
140. The Network for Public Health Law. Legal Interventions to Reduce Overdose Mortality: Naloxone Access and Overdose Good Samaritan Laws. The Network for Public Health Law website. Available from: https://www.networkforphl.org/-asset/qz5pvn/network-nalox one-10-4.pdf. [last accessed 19 Aug 2015].
141. Manufacture or sale of adulterated or misbranded items prohibited, MD Code, Health-General, 21-256 (1988).
142. Burris S, Norland J, Edlin BR. Legal aspects of providing naloxone to heroin users in the United States. Int J Drug Policy 2001;12:237-248.
143. Public Health Law Research. Naloxone Overdose Prevention Laws Map. LawAtlas Policy Surveillance Portal website. Available from: http://lawatlas.org/query?dataset=laws-regulating-administration-of-nalox one. [last accessed 18 Aug 2015].
144. Borg L. By end of August, CVS will offer Narcan without prescription to counter opiate overdoses. Providence Journal. Available from: http://www.providencejournal. com/article/20140823/LIFESTYLE/308239953 [last accessed 18 Aug 2015].
145. CVS Health. Boston Medical Center teams up with Rhode Island Hospital, CVS Health to address use of pharmacy-based naloxone to combat opioid addiction and overdoses. PR Newswire. Available from: http://www.prnewswire.com/news-releases/boston-medicalcenter-teams-up-with-rhode-island-hospital-cvshealth-to-address-use-of-pharmacy-based-naloxoneto-combat-opioid-addiction-and-overdoses-300124914. html [last accessed 18 Aug 2015].
146. Krasnow B. New Mexico pharmacists to prescribe antioverdose drug. Santa Fe New Mexican. Available from: http://www.santafenewmexican.com/news/health-and-science/new-mexico-pharmacists-to-prescribe-anti-over dose-drug/article-1399d567-d665-5017-b20a-9ff071dde447.html. March 26, 2014 [last accessed 18 Aug 2015].
147. License denial, suspension, or revocation, MD Code, Health Occupations, 14-404 (2015).
148. Unprofessional conduct-Definition, 59 Okl.St.Ann. 509 (2009).
149. Grounds for suspending, revoking or refusing to grant license, registration or certification; alternative medicine, O.R.S. 677.190 (2010).
150. National Alliance for Model State Drug Laws. Naloxone Access: Status of State Laws Map. National Alliance for Model State Drug Laws website. Available from: www. namsdl.org/library/6BD4D3A9-CC60-DE82-D2235BAD98403C12. [last accessed 19 Aug 2015].
151. Office of National Drug Control Policy, Office of Public Affairs. Fact sheet: Preventing, treating, and surviving overdose. The White House website. Available from: http://www.whitehouse.gov/sites/default/files/ondcp/prevention/overdose-fact-sheet. pdf. [last accessed 28 Nov 2014].
152. Executive Office of the President of the United States. National Drug Control Strategy. The White House website. Available from: https://www.whitehouse.gov/sites/default/files/ndcs-2014.pdf. [last accessed 18 Aug 2015].
153. Doyon S, Aks SE, Schaeffer S, American Academy of Clinical T, American College of Medical T, American Association of Poison Control C. Expanding access to naloxone in the United States. Clin Toxicol 2014;52:989-992.
154. Naloxone Overdose Prevention and Education (NOPE) Working Group. Naloxone Legislation Drafting Guide. Harm Reduction Coalition website. Available from: http://harmreduction.org/wp-content/uploads/2013/10/NOPE-Model-Naloxone-Legislation-with-NOPEDescription-and-Exhibits.pdf. [last accessed 28 Nov 2014].
155. National Alliance for Model State Drug Laws. About. National Alliance for Model State Drug Laws website. Available from: http://www.namsdl.org/about.cfm. [last accessed 18 Aug 2015].
156. National Alliance for Model State Drug Laws. Naloxone Access Statutes. National Alliance for Model State Drug Laws website. Available from: http://www.namsdl.org/library/6BFAE451-C122-D879-810C2AB405DBB9F2/. [last accessed 19 Aug 2015].
157. Lexicomp Online, Lexi-Drugs, Hudson, Ohio: Lexi-Comp, Inc.; August 18, 2015.
158. Oregon Health Authority. Opiate Overdose Treatment: Naloxone Training Protocol. Oregon Public Health Division website. Available from: https://public.health. oregon.gov/ProviderPartnerResources/EMSTraumaSystems/Documents/naloxone/naloxonetraining-protocol.pdf. [last accessed 18 Aug 2015].